PeptSense
Create account

Peptide research

Melanotan II — compounding legality overview

Melanotan II (MT-II) has a history of enforcement and safety scrutiny. Pharmacies and clinics should expect restrictive or unclear posture unless a clear federal chain step and state rule support compounding.

High-scrutiny melanocortin

Common names: MT-II, Melanotan 2

PeptSense tracks Melanotan II across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Restricted
Summary
Honest curation baseline (2026-08-01): Melanotan II has a history of enforcement / safety scrutiny in public FDA communications. Treated as restricted pending a more specific citation. Not a legal determination.
Citation
FDA compounding hub
Effective
Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.

Create account View pricing

Related research topics

  • melanotan II legality
  • melanotan compounding pharmacy

← All peptides · Resources hub